Case Report: Delayed Onset Multi-Organ Toxicities in a Melanoma Patient Achieving Complete Response to BRAF/MEK Inhibition
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Case Report: Delayed Onset Multi-Organ Toxicities in a Melanoma Patient Achieving Complete Response to BRAF/MEK Inhibition
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-03-31
DOI
10.3389/fonc.2022.836845
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies
- (2021) Ryan J. Sullivan et al. NATURE REVIEWS DRUG DISCOVERY
- IL-6 fuels durable memory for Th17 cell-mediated responses to tumors
- (2020) Hannah M Knochelmann et al. CANCER RESEARCH
- Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
- (2020) Reinhard Dummer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolving impact of long-term survival results on metastatic melanoma treatment
- (2020) Olivier Michielin et al. Journal for ImmunoTherapy of Cancer
- MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects
- (2020) Vivek Verma et al. NATURE IMMUNOLOGY
- BRAF targeting sensitizes resistant melanoma to cytotoxic T cells
- (2019) Cigdem Atay et al. CLINICAL CANCER RESEARCH
- Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
- (2019) Suzanne L. Topalian et al. JAMA Oncology
- When worlds collide: Th17 and Treg cells in cancer and autoimmunity
- (2018) Hannah M. Knochelmann et al. Cellular & Molecular Immunology
- Development of encorafenib for BRAF-mutated advanced melanoma
- (2018) Peter Koelblinger et al. CURRENT OPINION IN ONCOLOGY
- BRAF inhibitors stimulate inflammasome activation and interleukin 1 beta production in dendritic cells
- (2018) Eva Hajek et al. Oncotarget
- Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600–mutant metastatic melanoma
- (2018) Guy Ben-Betzalel et al. EUROPEAN JOURNAL OF CANCER
- Axial spondyloarthritis
- (2017) Joachim Sieper et al. LANCET
- Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade
- (2017) Khashayar Esfahani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study
- (2016) Yasuhiro Nakamura et al. JOURNAL OF DERMATOLOGY
- The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
- (2015) L. Liu et al. CLINICAL CANCER RESEARCH
- Vogt-Koyanagi-Harada-like Syndrome After CTLA-4 Inhibition With Ipilimumab for Metastatic Melanoma
- (2015) Jason N. Crosson et al. JOURNAL OF IMMUNOTHERAPY
- Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma
- (2015) Siwen Hu-Lieskovan et al. Science Translational Medicine
- The immune-related role of BRAF in melanoma
- (2014) Sara Tomei et al. Molecular Oncology
- Immunological consequences of selective BRAF inhibitors in malignant melanoma
- (2013) Bastian Schilling et al. OncoImmunology
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRAF inhibition improves tumor recognition by the immune system
- (2012) Marco Donia et al. OncoImmunology
- Human TH17 Cells Are Long-Lived Effector Memory Cells
- (2011) I. Kryczek et al. Science Translational Medicine
- Critical Regulation of Early Th17 Cell Differentiation by Interleukin-1 Signaling
- (2009) Yeonseok Chung et al. IMMUNITY
- Ocular and Systemic Autoimmunity after Successful Tumor-Infiltrating Lymphocyte Immunotherapy for Recurrent, Metastatic Melanoma
- (2009) Steven Yeh et al. OPHTHALMOLOGY
- Tumor-specific Th17-polarized cells eradicate large established melanoma
- (2008) P. Muranski et al. BLOOD
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now